Down‐regulation of cAMP‐dependent protein kinase by over‐activated calpain in Alzheimer disease brain

Impaired cognition and memory may be associated with down‐regulation of cAMP‐response element‐binding protein (CREB) in the brain in patients with Alzheimer disease, but the molecular mechanism leading to the down‐regulation is not understood. In this study, we found a selective reduction in the levels of the regulatory subunits (RIIα and RIIβ) and the catalytic subunit (Cβ) as well as the enzymatic activity of cAMP‐dependent protein kinase (PKA), which is the major positive regulator of CREB. We also observed that PKA subunits were proteolyzed by calpain and the levels of PKA subunits correlated negatively with calpain activation in the human brain. These findings led us to propose that in the brain in patients with Alzheimer disease, over‐activation of calpain because of calcium dysregulation causes increased degradation and thus decreased activity of PKA, which, in turn, contributes to down‐regulation of CREB and impaired cognition and memory.

[1]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[2]  K. Tomizawa,et al.  Truncation and Activation of Calcineurin A by Calpain I in Alzheimer Disease Brain* , 2005, Journal of Biological Chemistry.

[3]  S. McWeeney,et al.  Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models , 2006, Neurobiology of Aging.

[4]  S. Takeo,et al.  Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism‐induced defects in memory function and cerebral cyclic AMP signal transduction system in rats , 2002, British journal of pharmacology.

[5]  P. Cohen.  The structure and regulation of protein phosphatases. , 1989, Annual review of biochemistry.

[6]  Y. Ohizumi,et al.  Nobiletin restoring β-amyloid-impaired CREB phosphorylation rescues memory deterioration in Alzheimer's disease model rats , 2006, Neuroscience Letters.

[7]  B. Winblad,et al.  Subcellular distribution of protein phosphatases and abnormally phosphorylated τ in the temporal cortex from Alzheimer's disease and control brains , 1998, Journal of Neural Transmission.

[8]  A. Nairn,et al.  Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer's disease. , 2001, Journal of neural transmission. Supplementum.

[9]  R. Bourtchouladze,et al.  Targeting the CREB pathway for memory enhancers , 2003, Nature Reviews Drug Discovery.

[10]  J. Warsh,et al.  Altered cAMP‐dependent protein kinase subunit immunolabeling in post‐mortem brain from patients with bipolar affective disorder , 2003, Journal of neurochemistry.

[11]  G. McKnight,et al.  Distinct patterns of cAMP-dependent protein kinase gene expression in mouse brain , 1989, Neuron.

[12]  I. Grundke‐Iqbal,et al.  Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration , 2007, The European journal of neuroscience.

[13]  G. Jicha,et al.  cAMP-Dependent Protein Kinase Phosphorylations on Tau in Alzheimer’s Disease , 1999, The Journal of Neuroscience.

[14]  Sheng-tian Li,et al.  Critical Role of Calpain-mediated Cleavage of Calcineurin in Excitotoxic Neurodegeneration* , 2004, Journal of Biological Chemistry.

[15]  L. Tsai,et al.  Calpain-mediated Cleavage of the Cyclin-dependent Kinase-5 Activator p39 to p29* , 2002, The Journal of Biological Chemistry.

[16]  H. Braak,et al.  Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.

[17]  C. Schmitz‐Peiffer,et al.  Use of a synthetic dodecapeptide (malantide) to measure the cyclic AMP-dependent protein kinase activity ratio in a variety of tissues. , 1990, The Biochemical journal.

[18]  O. Vitolo,et al.  Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. , 2004, The Journal of clinical investigation.

[19]  I. Grundke‐Iqbal,et al.  Phosphatase Activity Toward Abnormally Phosphorylated τ: Decrease in Alzheimer Disease Brain , 1995, Journal of neurochemistry.

[20]  Veeranna,et al.  Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. , 2004, The American journal of pathology.

[21]  Fei Liu,et al.  Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation , 2005, The European journal of neuroscience.

[22]  J. Ryder,et al.  Inhibition of Aβ production and APP maturation by a specific PKA inhibitor , 2003 .

[23]  D. Levieux,et al.  Protein kinase Cα is a calpain target in cultured embryonic muscle cells , 2002, Molecular and Cellular Biochemistry.

[24]  Jianhua Shi,et al.  PKA modulates GSK‐3β‐ and cdk5‐catalyzed phosphorylation of tau in site‐ and kinase‐specific manners , 2006, FEBS letters.

[25]  I. Grundke‐Iqbal,et al.  Phosphoprotein Phosphatase Activities in Alzheimer Disease Brain , 1993, Journal of neurochemistry.

[26]  K. Olden,et al.  Requirement of Protein Kinase Cμ Activation and Calpain-mediated Proteolysis for Arachidonic Acid-stimulated Adhesion of MDA-MB-435 Human Mammary Carcinoma Cells to Collagen Type IV* , 2004, Journal of Biological Chemistry.

[27]  S. Josselyn,et al.  CREB, synapses and memory disorders: past progress and future challenges. , 2005, Current drug targets. CNS and neurological disorders.

[28]  I. Grundke‐Iqbal,et al.  Tau Becomes a More Favorable Substrate for GSK-3 When It Is Prephosphorylated by PKA in Rat Brain* , 2004, Journal of Biological Chemistry.

[29]  J. H. Schwartz,et al.  Regulatory subunits of cAMP-dependent protein kinases are degraded after conjugation to ubiquitin: a molecular mechanism underlying long-term synaptic plasticity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Palmeri,et al.  Amyloid-β Peptide Inhibits Activation of the Nitric Oxide/cGMP/cAMP-Responsive Element-Binding Protein Pathway during Hippocampal Synaptic Plasticity , 2005, The Journal of Neuroscience.

[31]  Mark P Mattson,et al.  Neuronal and glial calcium signaling in Alzheimer's disease. , 2003, Cell calcium.

[32]  John D. Scott,et al.  AKAP signalling complexes: focal points in space and time , 2004, Nature Reviews Molecular Cell Biology.

[33]  E R Kandel,et al.  Impaired hippocampal plasticity in mice lacking the Cbeta1 catalytic subunit of cAMP-dependent protein kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  L. Liu,et al.  Secretagogue-induced proteolysis of cAMP-dependent protein kinase in intact rat alveolar epithelial type II cells. , 1996, Biochimica et biophysica acta.

[35]  J. Scott,et al.  Type II regulatory subunits are not required for the anchoring-dependent modulation of Ca2+ channel activity by cAMP-dependent protein kinase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[36]  E. Kandel,et al.  Impaired Bidirectional Synaptic Plasticity and Procedural Memory Formation in Striatum-Specific cAMP Response Element-Binding Protein-Deficient Mice , 2006, The Journal of Neuroscience.

[37]  F. Raynaud,et al.  Implication of calpain in neuronal apoptosis , 2006, The FEBS journal.

[38]  P. Riederer,et al.  Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type , 1999, Brain Research.

[39]  M. Uhler,et al.  The Major Catalytic Subunit Isoforms of cAMP-dependent Protein Kinase Have Distinct Biochemical Properties in Vitro and in Vivo* , 1996, The Journal of Biological Chemistry.

[40]  P. Hyslop,et al.  Inhibition of abeta production and APP maturation by specific PKA inhibitors , 2000, Neurobiology of Aging.

[41]  R. Nixon,et al.  Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  E. Kandel,et al.  CREB, memory enhancement and the treatment of memory disorders: promises, pitfalls and prospects , 2003, Expert opinion on therapeutic targets.

[43]  A. Palmeri,et al.  Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.